T细胞淋巴瘤(TCL)是影响T淋巴细胞的非霍奇金淋巴瘤(NHL)类型。大约10%的NHL属于TCL,在某些亚洲地区这一比例达到30%以上。亚洲地区的下列亚型发病率较高:结外自然杀伤(NK)/T细胞淋巴瘤(ENKTL)、痘疱样淋巴瘤(HVL)、皮下脂膜炎样T细胞淋巴瘤(SPTCL)和成人T细胞白血病/淋巴瘤[6],与西方国家相比,患病率高出15%。
Featured media on Novotech’s leadership and impact.
Expert insights and real-world perspectives.
In-depth perspectives on forces shaping clinical research.
Tracking science and trends across therapeutic areas.
Hear from experts shaping clinical development.
Conversations with leaders shaping drug development.
A global CRO and scientific partner advancing drug development.
Our impact extends beyond trials, shaping healthier futures worldwide.
A collaborative, science-driven approach.
Recognized for excellence across the industry.
Decades of clinical and scientific leadership.
A global clinical research leader with an award-winning culture.
A culture that empowers growth, innovation, and impact.
Explore career opportunities at Novotech.
Benefits and recognition that support your success.
Experts collaborating to advance clinical research.
A commitment to your growth and development.
Start your career in clinical research with Novotech.
T细胞淋巴瘤(TCL)是影响T淋巴细胞的非霍奇金淋巴瘤(NHL)类型。大约10%的NHL属于TCL,在某些亚洲地区这一比例达到30%以上。亚洲地区的下列亚型发病率较高:结外自然杀伤(NK)/T细胞淋巴瘤(ENKTL)、痘疱样淋巴瘤(HVL)、皮下脂膜炎样T细胞淋巴瘤(SPTCL)和成人T细胞白血病/淋巴瘤[6],与西方国家相比,患病率高出15%。